Inactive Instrument

Elite Pharmaceuticals Inc Stock OTC Bulletin Board

Equities

US28659T2006

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Elite Pharmaceuticals Inc
Sales 2023 34.16M Sales 2024 56.63M Capitalization 157M
Net income 2023 3M Net income 2024 20M EV / Sales 2023 0.75 x
Net cash position 2023 3.94M Net Debt 2024 4.63M EV / Sales 2024 2.86 x
P/E ratio 2023
9.34 x
P/E ratio 2024
7.79 x
Employees -
Yield 2023 *
-
Yield 2024
-
Free-Float 73.16%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 63 13-07-31
Chief Executive Officer 69 02-10-31
Director of Finance/CFO 59 09-06-30
Members of the board TitleAgeSince
Director/Board Member 68 09-10-22
Director/Board Member 93 05-03-31
Director/Board Member 76 16-04-27
More insiders
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
More about the company